F
Filippo de Marinis
Researcher at European Institute of Oncology
Publications - 325
Citations - 25538
Filippo de Marinis is an academic researcher from European Institute of Oncology. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 51, co-authored 260 publications receiving 20243 citations. Previous affiliations of Filippo de Marinis include University of Milan & Autonomous University of Madrid.
Papers
More filters
Journal ArticleDOI
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell,Enric Carcereny,Radj Gervais,A. Vergnenegre,Bartomeu Massuti,Enriqueta Felip,Ramon Palmero,Ramon Garcia-Gomez,Cinta Pallares,Jose Miguel Sanchez,Rut Porta,Manuel Cobo,Pilar Garrido,Flavia Longo,Teresa Moran,A. Insa,Filippo de Marinis,Romain Corre,Isabel Bover,Alfonso Illiano,Eric Dansin,Javier de Castro,Michele Milella,Noemi Reguart,Giuseppe Altavilla,Ulpiano Jimenez,Mariano Provencio,Miguel Angel Moreno,J. Terrasa,Jose Muñoz-Langa,Javier Valdivia,Dolores Isla,Manuel Domine,Olivier Molinier,Julien Mazieres,Nathalie Baize,Rosario García-Campelo,Gilles Robinet,Delvys Rodriguez-Abreu,Guillermo Lopez-Vivanco,Vittorio Gebbia,Lioba Ferrera-Delgado,Pierre Bombaron,R. Bernabé,Alessandra Bearz,Angel Artal,Enrico Cortesi,Christian Rolfo,Maria Sanchez-Ronco,Ana Drozdowskyj,Cristina Queralt,Itziar de Aguirre,Jose Luis Ramirez,Jose Javier Sanchez,Miguel Angel Molina,Miquel Taron,Luis Paz-Ares +56 more
TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.
Journal ArticleDOI
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Achim Rittmeyer,Fabrice Barlesi,Daniel Waterkamp,Keunchil Park,Fortunato Ciardiello,Joachim von Pawel,Shirish M. Gadgeel,Toyoaki Hida,Dariusz M. Kowalski,Manuel Cobo Dols,Diego Cortinovis,Joseph W. Leach,Jonathan Polikoff,Carlos H. Barrios,Fairooz F. Kabbinavar,Osvaldo Arén Frontera,Filippo de Marinis,Hande Turna,Jong Seok Lee,Marcus Ballinger,Marcin Kowanetz,Pei He,Daniel S. Chen,Alan Sandler,David R. Gandara +24 more
TL;DR: Overall survival was significantly longer with atezolizumab in the ITT and PD-L1-expression populations, and overall survival improvement was similar in patients with squamous non-squamous lung cancer.
Journal ArticleDOI
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Giorgio V. Scagliotti,Purvish M. Parikh,Joachim von Pawel,Bonne Biesma,Johan Vansteenkiste,Christian Manegold,Piotr Serwatowski,Ulrich Gatzemeier,Raghunadharao Digumarti,Mauro Zukin,Jin S. Lee,Anders Mellemgaard,Keunchil Park,Shehkar Patil,Janusz Rolski,Tuncay Göksel,Filippo de Marinis,Lorinda Simms,Katherine P. Sugarman,David R. Gandara +19 more
TL;DR: This is the first prospective phase III study in NSCLC to show survival differences based on histologic type and cisplatin/pemetrexed provides similar efficacy with better tolerability and more convenient administration than cis platin/gemcitabine.
Journal ArticleDOI
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
Robert Pirker,José Rodrigues Pereira,Aleksandra Szczesna,Joachim von Pawel,Maciej Krzakowski,Rodryg Ramlau,Ihor Vynnychenko,Keunchil Park,Chih Teng Yu,Valentyn Ganul,Jae Kyung Roh,Emilio Bajetta,Kenneth J. O'Byrne,Filippo de Marinis,Wilfried Eberhardt,Thomas Goddemeier,M. Emig,Ulrich Gatzemeier +17 more
TL;DR: Addition of cetuximab to platinum-based chemotherapy represents a new treatment option for patients with advanced non-small-cell lung cancer.
Journal ArticleDOI
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
Yi-Long Wu,Masahiro Tsuboi,Jie He,Thomas John,C. Grohe,Margarita Majem,Jonathan W. Goldman,Konstantin Laktionov,Sang-We Kim,Terufumi Kato,Huu-Vinh Vu,Shun Lu,Kye-Young Lee,Charuwan Akewanlop,Chong-Jen Yu,Filippo de Marinis,Laura Bonanno,Manuel Domine,Frances A. Shepherd,Lingmin Zeng,Rachel Hodge,Ajlan Atasoy,Yuri Rukazenkov,Roy S. Herbst +23 more
TL;DR: In patients with stage IB to IIIA EGFR mutation-positive NSCLC, disease-free survival was significantly longer among those who received osimertinib than among thoseWho received placebo.